Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer

Nature Medicine

Volumn 13, Issue 7, 2007, Pages 828-835

  Nagaraj, Srinivas ^a   Gupta, Kapil ^b   Pisarev, Vladimir ^c   Kinarsky, Leo ^c   Sherman, Simon ^c   Kang, Loveleen ^a   Herber, Donna L ^a   Schneck, Jonathan ^b   Gabrilovich, Dmitry I ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXYNITRITE; REACTIVE OXYGEN METABOLITE; T LYMPHOCYTE RECEPTOR; TYROSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; CANCER; CD8+ T LYMPHOCYTE; CELL INTERACTION; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR MODEL; MOUSE; NITRATION; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN BINDING;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FEMALE; GENE DELETION; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNE TOLERANCE; MICE; MICE, INBRED C57BL; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NITRATES; RECEPTORS, ANTIGEN, T-CELL;

EID: 34447118098     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1609     Document Type: Article

References (43)

1. Pardoll, D. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21, 807-839 (2003).
2. + T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 5, 780-787 (1999).
3. Cuenca, A. et al. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res. 63, 9007-9015 (2003).
4. + T cell tolerance induced by bone marrow-derived immature myeloid cells. J. Immunol. 175, 4583-4592 (2005).
5. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66, 1123-1131 (2006).
6. Serafini, P., Borrello, I. & Bronte, V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 16, 53-65 (2006).
7. Gabrilovich, D. The mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4, 941-952 (2004).
8. Kusmartsev, S. & Gabrilovich, D.I. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol. Immunother. 55, 237-245 (2006).
9. Sinha, P., Clements, V.K., Miller, S. & Ostrand-Rosenberg, S. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol. Immunother. 54, 1137-1142 (2005).
10. Almand, B. et al. Increased production of immature myeloid cells in cancer patients. A mechanism of immunosuppression in cancer. J. Immunol. 166, 678-689 (2001).
11. Schmielau, J. & Finn, O.J. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res. 61, 4756-4760 (2001).
12. Zea, A.H. et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 65, 3044-3048 (2005).
13. Appleman, L.J., Tzachanis, D., Grader-Beck, T., van Puijenbroek, A.A. & Boussiotis, V.A. Helper T cell anergy: from biochemistry to cancer pathophysiology and therapeutics. J. Mol. Med. 78, 673-683 (2001).
14. Steinman, R.M. & Nussenzweig, M.C. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl. Acad. Sci. USA 99, 351-358 (2002).
15. Kusmartsev, S. & Gabrilovich, D.I. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J. Leukoc. Biol. 74, 186-196 (2003).
16. Dutz, J.P., Tsomides, T.J., Kageyama, S., Rasmussen, M.H. & Eisen, H.N. A cytotoxic T lymphocyte clone can recognize the same naturally occurring self peptide in association with a self and nonself class I MHC protein. Mol. Immunol. 31, 967-975 (1994).
17. Udaka, K., Wiesmuller, K.H., Kienle, S., Jung, G. & Walden, P. Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone. J. Immunol. 157, 670-678 (1996).
18. Quinn, M.T. The neutrophils respiratory burst oxidase. in The Neutrophils. New Outlook for Old Cells (ed. Gabrilovich, D.I.) 35-85 (Imperial College Press, London, 2005).
19. Squadrito, G.L. & Pryor, W.A. The formation of peroxynitrite in vivo from nitric oxide and superoxide. Chem. Biol. Interact. 96, 203-206 (1995).
20. + T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172, 989-999 (2004).
21. Regoli, F. & Winston, G.W. Quantification of total oxidant scavenging capacity of antioxidants for peroxynitrite, peroxyl radicals, and hydroxyl radicals. Toxicol. Appl. Pharmacol. 156, 96-105 (1999).
22. Balavoine, G.G. & Geletii, Y.V. Peroxynitrite scavenging by different antioxidants. Part I: convenient assay. Nitric Oxide 3, 40-54 (1999).
23. Smyth, M. et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to the interferon-γ-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 193, 661-670 (2000).
24. Kusmartsev, S. & Gabrilovich, D. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J. Immunol. 174, 4880-4891 (2005).
25. Zingarelli, B. et al. Oxidation, tyrosine nitration and cytostasis induction in the absence of inducible nitric oxide synthase. Int. J. Mol. Med. 1, 787-795 (1998).
26. Haqqani, A.S., Kelly, J.F. & Birnboim, H.C. Selective nitration of histone tyrosine residues in vivo in mutatect tumors. J. Biol. Chem. 277, 3614-3621 (2002).
27. Quint, P., Reutzel, R., Mikulski, R., McKenna, R. & Silverman, D.N. Crystal structure of nitrated human manganese superoxide dismutase: mechanism of inactivation. Free Radic. Biol. Med. 40, 453-458 (2006).
28. Wilkinson, I.B., MacCallum, H., Cockcroft, J.R. & Webb, D.J. Inhibition of basal nitric oxide synthesis increases aortic augmentation index and pulse wave velocity in vivo. Br. J. Clin. Pharmacol. 53, 189-192 (2002).
29. Nikitina, E.Y. et al. An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. Gene Ther. 9, 345-352 (2002).
30. + immune suppressive cells in the peripheral blood of patients with head and neck cancer. Ann. Otol. Rhinol. Laryngol. 109, 749-754 (2000).
31. Bronte, V., Serafini, P., Appoloni, E. & Zanovello, P. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J. Immunother. 24, 431-446 (2001).
32. Melani, C., Chiodoni, C., Forni, G. & Colombo, M.P. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102, 2138-2145 (2003).
33. + myeloid suppressor cells cause T cell dysfunction after traumatic stress. J. Immunol. 176, 2085-2094 (2006).
34. + myeloid cells inhibit development of antifungal Th1 immunity in mice with candidiasis. J. Immunol. 169, 3180-3190 (2002).
35. + T cell proliferation via an interferon-γ and nitric oxide dependent mechanism. J. Immunol. 167, 4293-4302 (2001).
36. Fahmy, T.M., Bieler, J.G., Edidin, M. & Schneck, J.P. Increased TCR avidity after T cell activation: a mechanism for sensing low-density antigen. Immunity 14, 135-143 (2001).
37. Maile, R. et al. Peripheral "CD8 tuning" dynamically modulates the size and responsiveness of an antigen-specific T cell pool in vivo. J. Immunol. 174, 619-627 (2005).
38. + T cell activation reflects altered T cell effector function. J. Immunol. 175, 1507-1515 (2005).
39. Alvarez, B. & Radi, R. Peroxynitrite reactivity with amino acids and proteins. Amino Acids 25, 295-311 (2003).
40. De Santo, C. et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc. Natl. Acad. Sci. USA 102, 4185-4190 (2005).
41. Sha, W.C. et al. Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice. Nature 335, 271-274 (1988).
42. Kusmartsev, S. et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 63, 4441-4449 (2003).
43. + myeloid cells. J. Immunol. 166, 5398-5406 (2001).